CLPS vs. IRWD
CLPS (CLPS Incorporation) and IRWD (Ironwood Pharmaceuticals, Inc.) are both stocks. CLPS operates in Information Technology Services (Technology), while IRWD operates in Drug Manufacturers - Specialty & Generic (Healthcare). Over the past 5 years, CLPS returned -22.25%/yr vs -20.98%/yr for IRWD. At a 0.07 correlation, their price movements are largely independent.
Performance
CLPS vs. IRWD - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CLPS achieves a 20.77% return, which is significantly higher than IRWD's 13.35% return.
CLPS
- 1D
- -2.34%
- 1M
- 7.87%
- YTD
- 20.77%
- 6M
- 10.93%
- 1Y
- -3.00%
- 3Y*
- -4.81%
- 5Y*
- -22.25%
- 10Y*
- —
IRWD
- 1D
- 7.91%
- 1M
- -2.55%
- YTD
- 13.35%
- 6M
- 18.27%
- 1Y
- 444.47%
- 3Y*
- -29.56%
- 5Y*
- -20.98%
- 10Y*
- -10.99%
CLPS vs. IRWD - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
CLPS CLPS Incorporation | 20.77% | -31.34% | 22.65% | 0.73% | -40.26% | -35.53% | -39.20% | 106.61% | -57.99% |
IRWD Ironwood Pharmaceuticals, Inc. | 13.35% | -23.93% | -61.28% | -7.67% | 6.26% | 2.37% | -14.43% | 28.47% | -40.46% |
Correlation
The correlation between CLPS and IRWD is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.05 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.03 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.05 |
Correlation (All Time) Calculated using the full available price history since May 24, 2018 | 0.07 |
Fundamentals
CLPS:
$28.66M
IRWD:
$636.76M
CLPS:
-$0.27
IRWD:
$0.88
CLPS:
0.09
IRWD:
1.81
CLPS:
$320.60M
IRWD:
$361.51M
CLPS:
$73.05M
IRWD:
$254.55M
CLPS:
-$4.37M
IRWD:
$204.95M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CLPS vs. IRWD — Risk / Return Rank
CLPS
IRWD
CLPS vs. IRWD - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for CLPS Incorporation (CLPS) and Ironwood Pharmaceuticals, Inc. (IRWD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CLPS | IRWD | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -4.46 | ||
| Sortino ratioReturn per unit of downside risk | -3.53 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.47 | -0.39 |
| Calmar ratioReturn relative to maximum drawdown | -0.06 | 10.28 | -10.34 |
| Martin ratioReturn relative to average drawdown | -0.09 | 22.47 | -22.56 |
Loading charts...
Drawdowns
CLPS vs. IRWD - Drawdown Comparison
The maximum CLPS drawdown since its inception was -95.00%, roughly equal to the maximum IRWD drawdown of -97.31%. Use the drawdown chart below to compare losses from any high point for CLPS and IRWD.
Loading charts...
Drawdown Indicators
| CLPS | IRWD | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.00% | -97.31% | +2.31% |
Max Drawdown (1Y)Largest decline over 1 year | -50.42% | -43.60% | -6.82% |
Max Drawdown (3Y)Largest decline over 3 years | -50.42% | -96.33% | +45.91% |
Max Drawdown (5Y)Largest decline over 5 years | -80.97% | -96.33% | +15.36% |
Max Drawdown (10Y)Largest decline over 10 years | — | -97.31% | — |
Current DrawdownCurrent decline from peak | -92.86% | -81.87% | -10.99% |
Average DrawdownAverage peak-to-trough decline | -81.23% | -39.38% | -41.85% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 34.39% | 19.90% | +14.49% |
Volatility
CLPS vs. IRWD - Volatility Comparison
CLPS Incorporation (CLPS) has a higher volatility of 17.76% compared to Ironwood Pharmaceuticals, Inc. (IRWD) at 16.90%. This indicates that CLPS's price experiences larger fluctuations and is considered to be riskier than IRWD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CLPS | IRWD | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.76% | 16.90% | +0.86% |
Volatility (6M)Calculated over the trailing 6-month period | 45.41% | 61.07% | -15.66% |
Volatility (1Y)Calculated over the trailing 1-year period | 78.94% | 101.48% | -22.54% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 64.36% | 73.28% | -8.92% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 103.69% | 61.08% | +42.61% |
Dividends
CLPS vs. IRWD - Dividend Comparison
Neither CLPS nor IRWD has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
CLPS CLPS Incorporation | 0.00% | 0.00% | 11.11% | 9.62% | 4.46% |
IRWD Ironwood Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
CLPS vs. IRWD - Financials Comparison
This section allows you to compare key financial metrics between CLPS Incorporation and Ironwood Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CLPS vs. IRWD - Profitability Comparison
CLPS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, CLPS Incorporation reported a gross profit of 19.55M and revenue of 85.09M. Therefore, the gross margin over that period was 23.0%.
IRWD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ironwood Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 106.51M. Therefore, the gross margin over that period was 0.0%.
CLPS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, CLPS Incorporation reported an operating income of 475.80K and revenue of 85.09M, resulting in an operating margin of 0.6%.
IRWD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ironwood Pharmaceuticals, Inc. reported an operating income of 72.57M and revenue of 106.51M, resulting in an operating margin of 68.1%.
CLPS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, CLPS Incorporation reported a net income of 83.02K and revenue of 85.09M, resulting in a net margin of 0.1%.
IRWD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ironwood Pharmaceuticals, Inc. reported a net income of 89.57M and revenue of 106.51M, resulting in a net margin of 84.1%.
Frequently Asked Questions
CLPS and IRWD have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLPS has higher volatility (17.76%) compared to IRWD (16.90%). In terms of maximum drawdown, CLPS dropped -95.00% vs IRWD's -97.31%.
IRWD currently has the higher Sharpe Ratio (4.43 vs -0.04), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CLPS and IRWD
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer